News & Events

Date Title and Summary Additional Formats
Toggle Summary Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer
Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer Whitehouse Station, NJ and Cambridge, MA, June 22, 2004 -- Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today
View HTML
Toggle Summary Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries
Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries Cambridge, MA, June 14, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that Vertex and Mitsubishi
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Discovery of Two New Classes of Compounds Targeting Cystic Fibrosis
Research Results Presented at CF Foundation's Williamsburg Conference
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C Cambridge, MA, June 8, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today the initiation of a Phase I clinical
HCV
View HTML
Toggle Summary Cystic Fibrosis Foundation Therapeutics Awards $21 Million to Vertex Pharmaceuticals Under Expanded Agreement
- New Collaboration Builds on Drug Discovery Progress at Vertex -
View HTML
Toggle Summary Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting
Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting Cambridge, MA, May 6, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today results of the voting at its 2004 Annual Meeting of Shareholders.
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV
Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV Tucson, AZ, May 4, 2004 -- New preclinical data for two proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex Pharmaceuticals
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress
Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress Cambridge, MA, April 26, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2004.
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches
Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches Berlin, Germany, April 16, 2004 -- New data for proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex
HCV
View HTML
Toggle Summary GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R)
GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R) Cambridge, MA, March 25, 2004 -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received a positive opinion from the European Committee for Proprietary
View HTML
Toggle Summary Vertex Researchers Report First Demonstration of Tumor Growth Suppression and Tumor Regression In Vivo with Aurora Kinase Inhibitors
- Study Published in Nature Medicine -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange
Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange Cambridge, MA, February 13, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has completed the exchange of approximately $153 million in aggregate principal amount of its 5% Convertible
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004
Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004 Cambridge, MA, February 11, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the year ended December 31, 2003.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007
Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007 Cambridge, MA, February 10, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that five holders of its existing 5% Convertible
View HTML
Toggle Summary Vertex and Novartis Amend Drug Discovery and Development Collaboration
Vertex and Novartis Amend Drug Discovery and Development Collaboration Cambridge, MA, February 3, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex and Novartis Pharma AG have amended their collaboration directed at targets in the protein kinase gene family.
View HTML
Toggle Summary Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
-Company to Provide Financial Guidance for 2004-
View HTML
Toggle Summary Vertex Researchers Publish Structure of FLT-3 Kinase in Molecular Cell
-Potential Mechanism Underlying Various Types of Leukemia Described-
View HTML
Toggle Summary Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS)
Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS) Cambridge, MA and Research Triangle Park, NC, January 20, 2004 -- The final 48-week results from the NEAT trial, an open-label, multi-center study
View HTML
Toggle Summary Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference
Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference Cambridge, MA, January 12, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented its 2003 accomplishments and 2004 outlook at the 22nd Annual JPMorgan
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results
Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results Cambridge, MA, October 24, 2001 — Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) reported consolidated financial results today for the three and nine months ended September 30, 2001.
View HTML